Lifetime Cost-effectiveness of Skin Cancer Prevention Through Promotion of Daily Sunscreen Use
Overview
Pharmacology
Public Health
Affiliations
Objectives: Health-care costs for the treatment of skin cancers are disproportionately high in many white populations, yet they can be reduced through the promotion of sun-protective behaviors. We investigated the lifetime health costs and benefits of sunscreen promotion in the primary prevention of skin cancers, including melanoma.
Methods: A decision-analytic model with Markov chains was used to integrate data from a central community-based randomized controlled trial conducted in Australia and other epidemiological and published sources. Incremental cost per quality-adjusted life-year was the primary outcome. Extensive one-way and probabilistic sensitivity analyses were performed to test the uncertainty in the base findings with plausible variation to the model parameters.
Results: Using a combined household and government perspective, the discounted incremental cost per quality-adjusted life-year gained from the sunscreen intervention was AU$40,890. Over the projected lifetime of the intervention cohort, this would prevent 33 melanomas, 168 cutaneous squamous-cell carcinomas, and 4 melanoma-deaths at a cost of approximately AU$808,000. The likelihood that the sunscreen intervention was cost-effective was 64% at a willingness-to-pay threshold of AU$50,000 per quality-adjusted life-year gained.
Conclusions: Subject to the best-available evidence depicted in our model, the active promotion of routine sunscreen use to white populations residing in sunny settings is likely to be a cost-effective investment for governments and consumers over the long term.
Bacardit A BMJ Public Health. 2025; 1(1):e000164.
PMID: 40017850 PMC: 11812704. DOI: 10.1136/bmjph-2023-000164.
Lagace F, Conte S, Mija L, Moustaqim-Barrette A, Mahmood F, LeBeau J Cancers (Basel). 2024; 16(17).
PMID: 39272952 PMC: 11394652. DOI: 10.3390/cancers16173093.
Lagace F, Noorah B, Conte S, Mija L, Chang J, Cattelan L Cancers (Basel). 2023; 15(15).
PMID: 37568569 PMC: 10417242. DOI: 10.3390/cancers15153753.
Dermatologic manifestations in patients with the Hermansky-Pudlak syndrome types 1 and 3.
Malave G, Izquierdo N, Sanchez N Orphanet J Rare Dis. 2022; 17(1):305.
PMID: 35907869 PMC: 9338640. DOI: 10.1186/s13023-022-02464-w.
Berman-Rosa M, Logan J, Ghazawi F, Le M, Conte S, Netchiporouk E Dermatology. 2022; 238(6):1006-1017.
PMID: 35679838 PMC: 9677843. DOI: 10.1159/000524949.